ProQR Therapeutics (PRQR) stock

RNA therapeutics , market cap $203M

RNA therapeutics for rare genetic diseases

Market cap $203M

$1.32

-5.04%

As of Monday's close · Live for Pro members at the open

Why is PRQR down?

Down 5.0% today, more than its biotech peers' 2.4%; no story names it yet.

Lags the market

Down 83% over five years while the S&P 500 rose 76%.

It filed a prospectus for $50.0M of shares on Jun 26, 2026. Its Oct 26 close of $1.24 was its lowest since Apr 17, 2025.

Sources: Price history, Oct 30, 2026; Prospectus supplement, Jun 26, 2026

Tell me next time PRQR moves

Free account, no card. An optional alert when PRQR moves or its score changes.

Or see it live, free until Wednesday morning. No account.

1 more reason, free with an account →The timeline, for Pro members.

Quality Score

-5

Poor

In its industry

#226of 291

Biotech

Checks firing

1of 14

Trending down

From 52-week high

-53.0%

Below the 200-day

PRQR's Quality Score rose 1 point on Mon, Nov 2, to -5. Trading was quieter than usual.

Follow PRQR's trial news. Pro members can get an alert when ProQR Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when PRQR files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextEnd of 2026“…data from the 9 mg/kg cohort and 12-week follow up from the ongoing Phase 1 study expected by year-end 2026”Trial data · SEC filing · Aug 13

Key facts on PRQR

Key facts on PRQR
Holding it back	Below its 200-day since September down 51% in a year
Latest filing	F-3, Jul 6 Registered shares for a later sale (F-3)

1 more reason behind PRQR's -5, free with an account →2 more reasons behind PRQR's -5, for Pro members.

PRQR in the news

TodayNo story names it yet.

What's next

Tue Nov 3: TIDES Europe 2026Industry event · date confirmed.

2 more dates ahead: conferences, for Pro members.

PRQR catalysts

Coming up

After its last 4 reports it closed -3.3% on average, higher 0 of 4 times.

3 more coming up and 3 past catalysts since 2022, with sizes and sources, for Pro members.Get in free →

What's next for PRQR

Next step the company has named

End of 2026“AX-0810 data from the 9 mg/kg cohort and 12-week follow up from the ongoing Phase 1 study expected by year-end 2026”Trial data · SEC filing · Aug 13

What it means: the first look at a trial’s main results, as the company reports them.

Lead program: AX-0810

2 more trials, 4 more milestones and 48 filings, for Pro members.

Dilution on the horizon

Shelf registration (F-3, filed Sep 30, 2024)
At-the-market share sales program (424B5, filed Oct 10, 2024)

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

CEO Daniel Anton de Boer bought 200,000 shares on Jul 31. 4 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Daniel Boer buys or sells

For Pro members: every trade, and Daniel Boer’s 4 filings and quotes.

Get an alert when PRQR files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 20 daysFDA decisionIn 20 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $385MDeramiocelFDA decision due (PDUFA)
In 20 daysFDA decisionIn 20 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $1.0BMolgramostimFDA decision due (PDUFA)
In 50 daysFDA decisionIn 50 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.9BLorundrostatFDA decision due (PDUFA)

11 more FDA dates and 102 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 143 dates, ranked →

Why PRQR scores -5

Poorfor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means

+1Chart checks 1 of 14 firing right now, one point each
−3Long-term trend below a falling 200-⁠day average, down over one year, down over two years

Size subtracts
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.

No effect today: Run-up, Growth, Dilution, Cash flow, Persistence, and News.

What every line is worth, and the reason behind it, on PRQR and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:40 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on PRQR and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

PRQR has 1 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on PRQR, and all 14 on every stock.Get in free →

PRQR RSI today: 36.7, below its 50-day and 200-day averages

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1436.7
Above 30, below 50.
MACD (12, 26, 9)Above signal
Crossed above its signal line 3 sessions ago.
50-day average$1.74
The price is 24.1% below it.
200-day average$1.69
The price is 21.9% below it.
50/200 crossGolden cross
The 50-day crossed above the 200-day on Aug 21.
ADX 1437.1
25 or more, with +DI below -DI.
Support
No swing low under the price in the last year.
Resistance$1.58
Swing high from Feb 18, 19.7% above the price.
52-week high$2.81
From Nov 3, 2025, 112.9% above the price.
52-week low$1.20
From Oct 27, 9.1% below the price.
Chart patternNone
No triangle, channel, or wedge in the last year.
Bollinger Bands (20, 2)Inside
The bands run from $1.18 to $1.68.
Volume0.7x
Against its 20-day average, for the time of day.

The deep dive on PRQR

What it does and how it makes money1 findingFor Pro members1 finding on what PRQR does and how it makes money, for Pro members
Who holds and trades it2 findingsNo open-market trades by insiders in 90 days; the last on file, CEO Daniel Anton de Boer bought $354K on Jul 31, 2026.Form 4, filed Aug 3, 2026

2 more findings on PRQR, each with its source, for Pro membersGet in free →

How PRQR ranks in Biotech

PRQR is #226 of 291 by Quality Score.

How PRQR ranks in Biotech
1	KNSAKiniksa Pharmaceuticals International	6/14	21
2	TGTXTG Therapeutics	8/14	19
3	AMGNAmgen	5/14	19
	PRMEPrime Medicine		Open for its score
	PROKProKidney		Open for its score
	PTCTPTC Therapeutics		Open for its score
	PTGXProtagonist Therapeutics		Open for its score
226	PRQRProQR Therapeutics	1/14	-5

When does PRQR report earnings, and what happens after?

Expected to report Thu Nov 5, before the open (in 3 days). Expected.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

-5.0%-0.6%-0.5%

Mar 12May 12Aug 13

Reported	When	Gap	Reaction	5 sessions
Aug 13, 2026Before open	Before open	+2.1%	-0.5%	+19.4%
May 12, 2026Before open	Before open	-0.6%	-0.6%	-6.2%
Mar 12, 2026Before open	Before open	0.0%	-5.0%	-5.0%

PRQR closed higher after 0 of its last 4 reports.

All 4 reports, and PRQR's Quality Score going into each

Everyone reporting earnings this week

PRQR share count over time

Offerings, shelves, and splits of PRQR, from its filings
From its filings	Filed
Registered shares for a later sale (F-3)	Jul 6, 2026
Raised $50M in a sale of shares, about 25% of its market value	Jun 26, 2026
Registered shares for a later sale (F-3)	Mar 13, 2025
Raised $63M in a sale of shares, about 31% of its market value	Oct 24, 2024

2 more offerings on file, for Pro members.

Insiders trading PRQR

PRQR insider trades

2 insiders bought $1.3M across 5 filings in the last 6 months. No open-⁠market sales on record. The newest:

BuyDaniel Anton de Boer$354KChief Executive Officerat $1.77 on Jul 31, filed Aug 3

BuyDaniel Anton de BoerChief Executive Officer$354Kat $1.77 on Jul 31, filed Aug 3

All 5 insider filings on PRQR from the last six months, for Pro members.Get in free →

All PRQR insider trades

PRQR's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Daniel Anton de BoerChief Executive Officer · 3 trades
Bart FiliusDirector · 2 trades

See insider trades by person

About ProQR Therapeutics

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.

187 employeesproqr.com

PRQR's score card

ProQR Therapeutics (PRQR): Quality Score -5, Poor, #226 of 291 in Biotech, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would turn PRQR's score around: 6 things
7 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayAug 3Daniel Anton de Boer bought PRQR$354K at $1.77, filed Aug 3

Alerts are optional.

See PRQR's 14 chart checks

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Nov 2, 2026: PRQR's Quality Score is -5 (Poor), #226 of 291 in Biotech. Insiders bought $1.3M in the last 6 months (Form 4).

Is PRQR a good stock to buy? What its Quality Score says

PRQR scores -5 today, which Breakaway calls Poor. It is #226 of 291 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 83% over five years while the S&P 500 rose 76%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is PRQR's Quality Score?

PRQR scores -5 today, which Breakaway calls Poor (below zero). That is #226 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind PRQR's -5.

Are insiders buying PRQR?

2 insiders bought $1.3M across 5 filings in the last 6 months. No open-⁠market sales on record. The newest is Daniel Anton de Boer, Chief Executive Officer, who bought $354K on Jul 31. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.